Immediate evolocumab after a heart attack improves LDL-cholesterol goals but not early cardiovascular outcomes

Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction in all-cause death or unplanned cardiovascular hospitalization was not observed compared with standard care. These were the main findings of the AMUNDSEN trial presented in a Hot Line session at ESC Congress 2026 and published simultaneously in JAMA.

≈